Literature DB >> 16702521

Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer.

John M Stulak1, Clive S Grant, David R Farley, Geoffrey B Thompson, Jon A van Heerden, Ian D Hay, Carl C Reading, J William Charboneau.   

Abstract

BACKGROUND: Cervical recurrences, predominantly in lymph nodes, occur in 14% to 30% of patients with papillary thyroid cancer (PTC). Postoperative surveillance for recurrent PTC increasingly includes thyrotropin-stimulated thyroglobulin and high-resolution ultrasonography (US). This combination commonly can detect recurrent disease as small as 5 mm. HYPOTHESIS: Preoperative US will increase detection and assessment of the extent of lymph node metastasis (LNM) in patients with PTC.
DESIGN: Retrospective cohort study.
SETTING: Tertiary care academic center. PATIENTS: From January 1, 1999, to December 31, 2004, a total of 770 patients were seen, 551 (381 female and 170 male; median age, 47 years; age range, 9-89 years) who underwent initial surgical management and 219 (154 female and 65 male; median age, 44 years; age range, 5-90 years) who underwent cervical reoperation for PTC. The US images were obtained preoperatively for 486 initial and 216 reoperative patients. Therapeutic radioactive iodine was administered to 151 (68.9%) of the reoperative patients before the subsequent operation (median dose, 5.6 x 10(9) Bq; range, 7.4 x 10(8)-3.7 x 10(10) Bq).
RESULTS: Ultrasonography identified nonpalpable lateral jugular LNMs in 70 (14.4%) of the patients undergoing initial exploration. Similarly, in reoperative patients, nonpalpable lateral LNMs were detected via US in 106 (64.2%), and 61 (28.2%) had LNMs detected in the central neck. Even when nodes were palpable preoperatively (37 [6.7%] of the initial and 56 [25.6%] of the reoperative patients), US assessment of the extent of LNM involvement altered the operation in 15 (40.5%) of the initial and 24 (42.9%) of the reoperative patients. The sensitivity, specificity, and positive predictive value for US were 83.5%, 97.7%, and 88.8% in initial patients, and 90.4%, 78.9%, and 93.9% in reoperative patients.
CONCLUSIONS: Overall, preoperative US detected nonpalpable LNMs in 231 (32.9%) of the 702 patients with PTC who underwent US, thereby altering the operative procedure performed. In addition, even in patients with palpable LNs, US helped to guide the extent of lymphadenectomy.

Entities:  

Mesh:

Year:  2006        PMID: 16702521     DOI: 10.1001/archsurg.141.5.489

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  88 in total

1.  Managing patients with a preoperative diagnosis of AJCC/UICC stage I (T1N0M0) papillary thyroid carcinoma: East versus West, whose policy is best?

Authors:  Ian D Hay
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

2.  Prediction of cervical lymph node metastasis in patients with papillary thyroid cancer using combined conventional ultrasound, strain elastography, and acoustic radiation force impulse (ARFI) elastography.

Authors:  Jun-Mei Xu; Xiao-Hong Xu; Hui-Xiong Xu; Yi-Feng Zhang; Le-Hang Guo; Lin-Na Liu; Chang Liu; Xiao-Wan Bo; Shen Qu; Mingzhao Xing; Xiao-Long Li
Journal:  Eur Radiol       Date:  2015-11-11       Impact factor: 5.315

Review 3.  Extent of surgery for papillary thyroid cancer: preoperative imaging and role of prophylactic and therapeutic neck dissection.

Authors:  Robin M Cisco; Wen T Shen; Jessica E Gosnell
Journal:  Curr Treat Options Oncol       Date:  2012-03

4.  The role of preoperative neck ultrasounds to assess lymph nodes in patients with suspicious or indeterminate thyroid nodules.

Authors:  Rashmi Roy; Guennadi Kouniavsky; Raghunandan Venkat; Erin A Felger; Zita Shiue; Eric Schneider; Martha A Zeiger
Journal:  J Surg Oncol       Date:  2011-10-17       Impact factor: 3.454

5.  Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer.

Authors:  Osama Al-Saif; William B Farrar; Mark Bloomston; Kyle Porter; Matthew D Ringel; Richard T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2010-03-23       Impact factor: 5.958

6.  Clinical-pathological changes in differentiated thyroid cancer (DTC) over time (1997-2010): data from the University Hospital "Maggiore della Carità" in Novara.

Authors:  L Pagano; M Caputo; M T Samà; V Garbaccio; M Zavattaro; M G Mauri; F Prodam; P Marzullo; R Boldorini; G Valente; G Aimaretti
Journal:  Endocrine       Date:  2012-10       Impact factor: 3.633

7.  Preoperative ultrasound evaluation of laterocervical lymph nodes: timing and experience modify the treatment of patients with differentiated thyroid cancer.

Authors:  Marica Grasso; Alessandro Puzziello; Maurizio De Palma
Journal:  Updates Surg       Date:  2019-01-02

8.  Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006.

Authors:  Clive S Grant; John M Stulak; Geoffrey B Thompson; Melanie L Richards; Carl C Reading; Ian D Hay
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

Review 9.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

10.  Prognostic Value of the Number of Retrieved Lymph Nodes in Pathological Nx or N0 Classical Papillary Thyroid Carcinoma.

Authors:  Tae-Yon Sung; Jong Ho Yoon; Dong Eun Song; Yu-Mi Lee; Tae-Yong Kim; Ki-Wook Chung; Won Bae Kim; Young Kee Shong; Suck Joon Hong
Journal:  World J Surg       Date:  2016-08       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.